Clinical Trials on Acute Lymphoblastic Leukemia

Total 18590 results

Michael Burke
Amgen

Recruiting

Blinatumomab Bridging Therapy

Refractory B Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

T-cell Childhood Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic Leukemia

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia

United States
M.D. Anderson Cancer Center

Withdrawn

STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis

Acute Myeloid Leukemia (AML) | Refractory T Acute Lymphoblastic Leukemia

United States
Nanfang Hospital of Southern Medical University

Recruiting

CD19-CAR-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia Not Having Achieved Remission

China
Massachusetts General Hospital
Millennium Pharmaceuticals, Inc.

Completed

Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | B-cell Adult Acute Lymphoblastic Leukemia | T-cell Adult Acute Lymphoblastic Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)

Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Childhood B Acute Lymphoblastic Leukemia

United States, Canada, Australia
H. Lee Moffitt Cancer Center and Research Institute
Jazz Pharmaceuticals

Completed

Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Relapsed Acute Lymphoblastic Leukemia | Lymphoid Leukemia

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients (ENSIGN)

B-cell Acute Lymphoblastic Leukemia | Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia

United States
National Institute of Cancerología

Unknown

RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic Factors in AML

Acute Myeloblastic Leukemia | Acute Lymphoblastic Leukemia.

Mexico
Abramson Cancer Center of the University of Pennsylvania

Withdrawn

Study of Efficacy and Safety of CTL019 in Adult ALL Patients

B-cell Acute Lymphoblastic Leukemia | Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-75276617 in Participants With Acute Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Leukemias

United States, United Kingdom, France, Spain, Australia
Hebei Senlang Biotechnology Inc., Ltd.
The Second Hospital of Hebei Medical University

Recruiting

CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

Childhood Acute Lymphoblastic Leukemia

China
Julio Barredo, MD
Takeda

Completed

Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL

Refractory Acute Lymphoblastic Leukemia | Relapsed Acute Lymphoblastic Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Childhood B Acute Lymphoblastic Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Childhood B Acute Lymphoblastic Leukemia

United States, Canada, Australia, New Zealand, Switzerland
Beijing GoBroad Hospital

Not yet recruiting

CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction

Acute Lymphoblastic Leukemia, in Relapse | B-cell Acute Lymphoblastic Leukemia | Refractory Acute Lymphoid Leukemia

China
University of Washington
National Cancer Institute (NCI)

Terminated

Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | Recurrent Acute Lymphoblastic Leukemia | Minimal Residual Disease | T Acute Lymphoblastic Leukemia

United States
KK Women's and Children's Hospital
National University Hospital, Singapore; Singapore General Hospital

Recruiting

Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia

Lymphoblastic Leukemia, Acute, Childhood | Lymphoblastic Leukemia | Lymphoblastic Leukemia, Acute Adult | Lymphoblastic Leukemia in Children | CAR

Singapore
Armaceutica, Inc.
Ifakara Health Research and Development Centre; Uganda Cancer Institute; African... and other collaborators

Recruiting

Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL)

Senegal
Grupo Espanol de trasplantes hematopoyeticos y...

Completed

Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia (DASA-TRAS)

Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

Spain
Chinese PLA General Hospital
Shenzhen University General Hospital

Unknown

Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia

Refractory Acute Lymphoblastic Leukemia | Relapsed Acute Lymphoblastic Leukemia

China
Federal Research Institute of Pediatric Hematology...

Recruiting

Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2019 Pilot

Childhood Acute Lymphoblastic Leukemia

Russian Federation
Federal Research Institute of Pediatric Hematology...

Recruiting

Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015) (ALL-MB 2015)

Childhood Acute Lymphoblastic Leukemia

Armenia, Belarus, Kyrgyzstan, Russian Federation, Uzbekistan
Federal Research Institute of Pediatric Hematology...

Unknown

Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2008 (ALL-MB 2008)

Childhood Acute Lymphoblastic Leukemia

Russian Federation, Belarus, Uzbekistan
Amgen

Not yet recruiting

Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

B Precursor Acute Lymphoblastic Leukemia | Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
Shanghai Children's Medical Center
Miltenyi Biomedicine GmbH

Unknown

MB-CART19.1 in Patients With R/R ALL

Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory
Medical College of Wisconsin
University of Wisconsin, Madison; Amgen

Recruiting

Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT

B-cell Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | B-Cell ALL, Childhood

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

DNA Analysis of Tumor Tissue Samples From Young Patients With Acute Lymphoblastic Leukemia

Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic Leukemia

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia

Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic Leukemia

United States
Emory University

Terminated

AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia (BMTAMD3100)

Pediatric Acute Myeloblastic Leukemia, Relapsed | Pediatric Acute Lymphoblastic Leukemia, Relapsed

United States
Washington University School of Medicine
National Cancer Institute (NCI); National Institutes of Health (NIH); The Leukemia...

Terminated

BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma

T-Acute Lymphoblastic Leukemia | Adult T Lymphoblastic Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Ph-Like Acute Lymphoblastic Leukemia | Refractory Ph-Like Acute Lymphoblastic Leukemia

United States
Beijing GoBroad Hospital

Recruiting

Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients

Acute Lymphoblastic Leukemia, in Relapse | B-cell Acute Lymphoblastic Leukemia | Refractory Acute Lymphoid Leukemia

China
Instituto do Cancer do Estado de São Paulo
Libbs Farmacêutica LTDA

Recruiting

Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia With Failed Remission

Brazil
Beijing Boren Hospital

Recruiting

Study of Anti-CD22 CAR-T Cells Treating Leukemia Children

Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia

China
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission

Childhood Acute Lymphoblastic Leukemia in Remission

United States, Canada, Australia
Therapeutic Advances in Childhood Leukemia Consortium

Terminated

Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia

Relapsed Acute Lymphoblastic Leukemia | Relapsed Acute Myelogenous Leukemia

United States
National Cancer Institute (NCI)

Completed

Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia

Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Untreated Adult Acute Lymphoblastic Leukemia

United States
Versailles Hospital

Recruiting

Registry of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (ALLTARGETOBS)

T-cell Acute Lymphoblastic Leukemia | Relapsed/Refractory Acute Lymphoblastic Leukemia

France
Shenzhen Geno-Immune Medical Institute

Recruiting

NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL

T-Cell Acute Lymphoblastic Leukemia

China
Beijing Boren Hospital

Recruiting

Donor-Derived CD5 CAR T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia

T-Cell Acute Lymphoblastic Leukemia

China
Queen Mary University of London
Gilead Sciences

Unknown

Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL) (MARALL)

Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia

United Kingdom
University of Washington
National Cancer Institute (NCI)

Completed

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Refractory Acute Leukemia of Ambiguous Lineage | Recurrent Acute Leukemia of Ambiguous Lineage

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Acute Myeloid Leukemia in Remission | Adult Acute Lymphoblastic... and other conditions

United States
IRCCS SYNLAB SDN
Santobono-Pausilipon Hospital

Recruiting

Unravelling the Role of KCTD Protein Family in the Clinical Management of Childhood Acute Lymphoblastic Leukemias

Childhood Acute Lymphoblastic Leukemia

Italy
St. Jude Children's Research Hospital

Active, not recruiting

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Refractory

United States
University of Pennsylvania

Active, not recruiting

CART22 Alone or in Combination With huCART19 for ALL

Refractory Acute Lymphoblastic Leukemia | Chemotherapy Resistant Acute Lymphoblastic Leukemia

United States

Clinical Trials on Acute Lymphoblastic Leukemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations